Free Trial

Aequus Pharmaceuticals Q4 2023 Earnings Report

Aequus Pharmaceuticals logo
C$0.0050 -0.01 (-50.00%)
As of 03/25/2025

Aequus Pharmaceuticals EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aequus Pharmaceuticals Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aequus Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Aequus Pharmaceuticals Earnings Headlines

Aequus Pharmaceuticals Reports Revenue Growth Amid Restructuring
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Aequus Pharmaceuticals Inc. (AQSZF)
Aequus Pharmaceuticals Inc (AQS)
See More Aequus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aequus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aequus Pharmaceuticals and other key companies, straight to your email.

About Aequus Pharmaceuticals

Aequus Pharmaceuticals (CVE:AQS) operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

View Aequus Pharmaceuticals Profile

More Earnings Resources from MarketBeat